Disi Medical Completes Tens of Millions RMB Pre-A++ Financing to Advance NMPA Registration of Ophthalmic Surgical Robot, WinX Capital Continues as Exclusive Financial Advisor

Hangzhou Dessight Biomedical Co. Ltd. (hereinafter referred to as “Dessight Biomedical”) recently announced the successful completion of its Pre-A++ financing round, amounting to tens of millions of yuan. This marks the company’s third fundraising event within a year. The round was led by Fortune Capital, with WinX Capital continuing to serve as the exclusive financial advisor.The funds raised will be primarily used to advance the NMPA registration of ophthalmic surgical robots and to drive the R&D of product lines such as microsurgical robots.

Dessight Biomedical, established in July 2021, is a national technology-based small and medium-sized enterprise specializing in the field of supermicrosurgery. Its founding team hails from Germany’s top global robotics and artificial intelligence laboratories as well as a Fortune 500 German pharmaceutical company. To date, Dessight Biomedical has filed for and been granted multiple invention patents in the United States and China, won numerous awards in competitions both domestically and internationally, and is collaborating with several renowned medical institutions in China on various research projects in the field of surgical robotics.

The eye is the most delicate and complex organ in the human body.

The development of ophthalmic surgical robots is crucial for addressing pain points in fundus and microsurgical procedures. Leveraging its personalized integration of medicine and engineering, master-slave control-based multi-degree-of-freedom systems, and proprietary flexible structural technology, Dessight Biomedical has successfully achieved a motion precision as high as 3 micrometers. The company maintains a global leading position in product technology and R&D progress. Since the “Dessight MicroBlade” ophthalmic surgical robot completed the first human clinical application case in Asia at Zhejiang Provincial People’s Hospital in July 2023, it has successfully been used in multiple research and clinical cases, with favorable postoperative outcomes. Currently, the company has officially initiated clinical trials for NMPA registration to further validate the safety and efficacy of its product. In addition, the company’s microsurgical robot has entered the prototype development stage, marking Dessight Biomedical’s continuous innovation in the field of medical robotics and its contribution to the future development of medical technology.

“Dessight MicroBlade” First Clinical Application

Dr. Di Cui, CEO of Dessight Biomedical“The successful application of the ‘Dessight MicroBlade’ ophthalmic surgical robot in scientific research and clinical settings has greatly boosted our team’s confidence. We appreciate Fortune Capital’s recognition of Dessight Biomedical and its strong support as the ophthalmic surgical robot enters a new phase of registration-focused clinical trials. Moving forward, we will further expand the application of medical robots in the field of microsurgery, represented by our ophthalmic surgical robot, aiming to become the dexterous and precise hands of surgeons in ultra-microsurgical procedures and bring hope to patients with previously untreatable conditions.”

Dr. Yu Peifeng, Investment Director at Fortune CapitalHe stated, “Unlike surgical robots for specialties such as laparoscopy and orthopedics, fundus and supermicrosurgical robots address critical pain points in fundus and microsurgical procedures due to their ultra-high precision. They serve as a vital necessity rather than a mere enhancement, reflecting strong essential demand. Dessight Biomedical is a leader in this field. We have tracked the company for eighteen months, witnessing the exceptional execution efficiency of the team led by Dr. Cui. We look forward to Dessight’s continued success, overcoming challenges and achieving steady, long-term growth.”

Zou Guowen, Founding Partner of WinX CapitalWinX Capital stated: “We are honored to have served as the exclusive financial advisor for Dessight Biomedical’s financing rounds consecutively. As a high-quality enterprise in the surgical robotics industry, Dessight Biomedical has successfully navigated market cycles and secured three rounds of financing within a single year, fully demonstrating strong recognition from the investment community. The company’s surgical robotic products transcend the physiological limitations of manual dexterity, enabling surgeons to perform ultra-complex procedures with significant clinical necessity. We look forward to their early market launch to benefit more patients.”

Fortune Capital is one of the most influential venture capital firms in China. Established in 2000, it manages funds totaling nearly RMB 50 billion and has invested in over 730 companies. Thanks to its outstanding performance, Fortune Capital has consistently ranked among the top in evaluations conducted by authoritative institutions such as the China Venture Capital Association, Zero2IPO Group, CVSource, and Financing China. It has been listed among Zero2IPO’s “Top 50 Best Venture Capital Firms in China” for 23 consecutive years, ranking first in 2012 and 2015, and has remained among the top three domestic venture capital firms for the past decade. Furthermore, in the evaluations of private equity fund managers investing insurance funds conducted by the Insurance Asset Management Association of China in 2020, 2021, and 2022, Fortune Capital was rated as a Class A institution with high scores for three consecutive years.

WinX Capital is a leading investment bank in China’s healthcare sector, with headquarters in Beijing and Shanghai, covering more than 3,000 active institutional investors and industrial groups. It has received numerous accolades, including “No. 1 Financial Advisor in Healthcare for 2022” by First New Voice, “Top 2 Best Financial Advisors in Healthcare for 2021–2022” by Qimingpian & New Voice Innovation Services, and “Top 5 Healthcare Financial Advisors of the Year” at the 2022–2023 Pengcheng Awards by VCBeat.